Literature DB >> 18006785

Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.

Aaron C Spalding1, Richard Watson, Mary E Davis, Alex C Kim, Theodore S Lawrence, Edgar Ben-Josef.   

Abstract

PURPOSE: Aberrant activation of protein kinase Cbeta (PKCbeta) by pancreatic cancer cells facilitates angiogenesis and tumor cell survival. Targeting PKCbeta with enzastaurin, a well-tolerated drug in clinical trials, would be expected to radiosensitize pancreatic tumors through direct antitumor and antivascular effects. EXPERIMENTAL
DESIGN: We tested the hypothesis that enzastaurin radiosensitizes pancreatic cancer cells in culture and in vivo through inhibition of PKCbeta. We analyzed pancreatic cancer xenografts for growth delay and microvessel density after treatment with enzastaurin, radiation, or both. We determined the effect of radiation and enzastaurin on glycogen synthase kinase 3beta, a mediator of cell death in culture and in vivo.
RESULTS: At concentrations attained in patients, enzastaurin reduced levels of active PKCbeta measured by phosphorylation at Thr(500) in culture and in xenografts. Enzastaurin alone did not affect pancreatic cancer cell survival, proliferation, or xenograft growth. However, enzastaurin radiosensitized pancreatic cancer cells in culture by colony formation assay. Enzastaurin alone decreased microvessel density of pancreatic cancer xenografts without appreciable effects on tumor size. When combined with radiation, enzastaurin increased radiation-induced tumor growth delay with a corresponding decrease in microvessel density. Enzastaurin inhibited radiation-induced phosphorylation of glycogen synthase kinase 3beta at Ser(9) in pancreatic cancer cells in culture and in tumor xenografts, suggesting a possible mechanism for the observed radiosensitization.
CONCLUSIONS: Enzastaurin inhibits PKCbeta in pancreatic cancer cells in culture, enhancing radiation cytotoxicity. Additional antivascular effects of enzastaurin were observed in vivo, resulting in greater radiosensitization. These results provide the rationale for a clinical trial in locally advanced pancreatic cancer combining enzastaurin with radiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006785     DOI: 10.1158/1078-0432.CCR-07-0454

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer.

Authors:  Richard L Watson; Aaron C Spalding; Steven P Zielske; Meredith Morgan; Alex C Kim; Guido T Bommer; Hagit Eldar-Finkelman; Thomas Giordano; Eric R Fearon; Gary D Hammer; Theodore S Lawrence; Edgar Ben-Josef
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

Review 2.  Protein kinase C isoforms in the normal pancreas and in pancreatic disease.

Authors:  Alicia K Fleming; Peter Storz
Journal:  Cell Signal       Date:  2017-08-18       Impact factor: 4.315

3.  Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.

Authors:  Christopher D Willey; Dakai Xiao; Tianxiang Tu; Kwang Woon Kim; Luigi Moretti; Kenneth J Niermann; Mohammed N Tawtawy; Chad C Quarles; Bo Lu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-10       Impact factor: 7.038

4.  Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.

Authors:  Aaron C Spalding; Benjamin D Zeitlin; Kari Wilder-Romans; Mary E Davis; Jacques E Nor; Theodore S Lawrence; Edgar Ben-Josef
Journal:  Transl Oncol       Date:  2008-12       Impact factor: 4.243

5.  Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.

Authors:  Donald A Richards; Paul R Kuefler; Carlos Becerra; Lalan S Wilfong; Robert H Gersh; Kristi A Boehm; Feng Zhan; Lina Asmar; Scott P Myrand; Rebecca R Hozak; Luping Zhao; John F Gill; Brian P Mullaney; Coleman K Obasaju; Steven J Nicol
Journal:  Invest New Drugs       Date:  2009-08-28       Impact factor: 3.850

6.  Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy.

Authors:  Qiang Zhang; Mahaveer S Bhojani; Edgar Ben-Josef; Aaron C Spalding; Rork Kuick; Yi Sun; Meredith A Morgan
Journal:  J Carcinog Mutagen       Date:  2013-08-16

7.  Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.

Authors:  C Tekle; E Giovannetti; J Sigmond; J R Graff; K Smid; G J Peters
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

8.  Protein kinase C: an attractive target for cancer therapy.

Authors:  Barbara Marengo; Chiara De Ciucis; Roberta Ricciarelli; Maria A Pronzato; Umberto M Marinari; Cinzia Domenicotti
Journal:  Cancers (Basel)       Date:  2011-02-01       Impact factor: 6.639

9.  Preoperative chemoradiotherapy in rectal cancer induces changes in the expression of nuclear β-catenin: prognostic significance.

Authors:  Jaime Gomez-Millan; Lydia Perez; Ines Aroca; Maria Del Mar Delgado; Vanessa De Luque; Alicia Román; Esperanza Torres; Soraya Ramos; Sofia Perez; Eloisa Bayo; Jose Antonio Medina
Journal:  BMC Cancer       Date:  2014-03-15       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.